NYSEMKT: STXS
Stereotaxis Inc Stock

$2.40-0.03 (-1.23%)
Updated Feb 10, 2025
STXS Price
$2.40
Fair Value Price
N/A
Market Cap
$203.35M
52 Week Low
$1.66
52 Week High
$3.29
P/E
-8.89x
P/B
18.8x
P/S
6.96x
PEG
N/A
Dividend Yield
N/A
Revenue
$25.14M
Earnings
-$21.57M
Gross Margin
56.1%
Operating Margin
-85.79%
Profit Margin
-91.1%
Debt to Equity
3.21
Operating Cash Flow
-$12M
Beta
0.96
Next Earnings
Mar 3, 2025
Ex-Dividend
N/A
Next Dividend
N/A

STXS Overview

Stereotaxis Incorporated manufactures and sells robotic systems, instruments, and information system for the interventional laboratory sector in the U.S. and internationally. Its robotic magnetic navigation (RMN) systems include the Genesis RMN and Niobe, which enable physicians to complete complex procedures by providing image-guided delivery of catheters and guidewires through the blood vessels and chambers of the heart to treatment sites. The company also offers Vdrive, a system that offers navigation and stability for diagnostic and therapeutic devices. Stereotaxis was incorporated in 1990 and is headquartered in Saint Louis, MO.

Zen Rating

Our proven quant model uses 115 proprietary factors, including AI, to determine STXS's potential to beat the market

CHold
  • Stocks with a Zen Rating of Hold (C) had an average return of +7.53% per year. Learn More

Zen Rating Component Grades

C
Value
B
Growth
C
Momentum
C
Sentiment
C
Safety
D
Financials
C
Artificial Intelligence
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.

Industry: Medical

Industry Rating
A
STXS
Ranked
#39 of 49

Top Ranked Stocks in Industry

Name / TickerPriceZen Rating
$8.12A
$33.25A
$4.65A
View Top Medical Stocks

Be the first to know about important STXS news, forecast changes, insider trades & much more!

STXS News

Overview

Due Diligence Score

Industry Average (28)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how STXS scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.

Due Diligence Checks

STXS is unprofitable, so we are unable to calculate its intrinsic value according to an updated version of Benjamin Graham's Formula from "The Intelligent Investor"
Below Benjamin Graham Formula Value Valuation
STXS is poor value based on its book value relative to its share price (18.8x), compared to the US Medical Instruments & Supplies industry average (4.11x)
P/B vs Industry Valuation
STXS is unprofitable, so we... subscribe to Premium to read more.
PEG Value Valuation
There are 30 more STXS due diligence checks available for Premium users.

Valuation

STXS price to earnings (PE)

For valuing profitable companies with steady earnings

Company
-8.89x
Industry
40.12x
Market
31x

STXS price to book (PB)

For valuing companies that are loss-making or have lots of physical asset

Company
18.8x
Industry
4.11x
STXS is poor value based... subscribe to Premium to read more.
P/B vs Industry Valuation

STXS's financial health

Profit margin

Revenue
$9.2M
Net Income
-$6.2M
Profit Margin
-70.9%
STXS's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
STXS's profit margin has decreased... subscribe to Premium to read more.
Profit Margin Growth Financials

Assets to liabilities

Assets
$50.9M
Liabilities
$34.7M
Debt to equity
3.21
STXS's short-term assets ($28.81M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
STXS's short-term assets ($28.81M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
STXS's debt has increased relative... subscribe to Premium to read more.
Shrinking Debt Financials
STXS's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials

Cash flow

Operating
-$4.3M
Investing
$98.0k
Financing
$80.0k
STXS's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials

STXS vs Medical Stocks

TickerZen RatingMarket Cap1d %P/EP/B
STXSC$203.35M-1.23%-8.89x18.80x
UTMDC$204.96M+0.96%14.15x1.65x
KRMDA$213.14M+0.65%-18.60x12.02x
INFUA$172.66M+3.84%135.33x3.11x
ZJYLC$158.11M+22.87%50.50x5.49x

Stereotaxis Stock FAQ

What is Stereotaxis's quote symbol?

(NYSEMKT: STXS) Stereotaxis trades on the NYSEMKT under the ticker symbol STXS. Stereotaxis stock quotes can also be displayed as NYSEMKT: STXS.

If you're new to stock investing, here's how to buy Stereotaxis stock.

What is the 52 week high and low for Stereotaxis (NYSEMKT: STXS)?

(NYSEMKT: STXS) Stereotaxis's 52-week high was $3.29, and its 52-week low was $1.66. It is currently -27.05% from its 52-week high and 44.58% from its 52-week low.

How much is Stereotaxis stock worth today?

(NYSEMKT: STXS) Stereotaxis currently has 84,729,507 outstanding shares. With Stereotaxis stock trading at $2.40 per share, the total value of Stereotaxis stock (market capitalization) is $203.35M.

Stereotaxis stock was originally listed at a price of $71.35 in Aug 12, 2004. If you had invested in Stereotaxis stock at $71.35, your return over the last 20 years would have been -96.64%, for an annualized return of -15.6% (not including any dividends or dividend reinvestments).

How much is Stereotaxis's stock price per share?

(NYSEMKT: STXS) Stereotaxis stock price per share is $2.40 today (as of Feb 10, 2025).

What is Stereotaxis's Market Cap?

(NYSEMKT: STXS) Stereotaxis's market cap is $203.35M, as of Feb 11, 2025.

Market cap (market capitalization) is the total market value of a publicly traded company's outstanding shares.

Stereotaxis's market cap is calculated by multiplying STXS's current stock price of $2.40 by STXS's total outstanding shares of 84,729,507.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.